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While the envelope glycoprotein of vesicular stomatitis virus (VSV-G) is widely used for pseudotyping of
lentiviral vectors, sub-optimal gene transfer into certain cell types and its sensitivity to inactivation by
human complement hinders its broader applications. To ﬁnd alternative candidates, here we evaluated
two serologically distinct novel viral envelopes derived from Chandipura (CNV-G) and Piry (PRV-G)
vesiculoviruses. Both permitted generation of high titer psuedotyped lentiviral vectors with a capacity for
high efﬁciency gene transfer into various cell types from different species. In human lymphoid and
hematopoietic stem cells, their transduction efﬁciency was signiﬁcantly lower than that of VSV-G.
However, both novel envelopes were found to be more resistant to inactivation by human serum com-
plement compared to VSV-G. Thus CNV-G and PRV-G envelopes can be harnessed for multiple uses in the
future based on the cell type that needs to be gene transduced and possibly for in vivo gene transfer.
& 2015 Elsevier Inc. All rights reserved.Introduction
Gene therapy strategies are currently being widely evaluated
for the treatment of genetic disorders, cancer, neurological con-
ditions and immuno-deﬁciency diseases including AIDS (Anderson
et al., 2007; Nagabhushan Kalburgi et al., 2013; Cicalese and Aiuti,
2015; Roth and Cristiano, 1997; Matrai et al., 2010; Emeagi et al.,
2013). Instead of using typical drugs for treatment, gene therapy
involves introduction of transgenes into host cells to enable
expression of therapeutic proteins or nucleic acids, such as siRNAs
to restore normal functions or mediate anti-viral protection. Viral
vectors are commonly used for gene transfer, of which lentiviral
vectors (LV) constitute the most popular vehicles for delivering
transgenes due to their capacity to transduce non-dividing and
terminally differentiated cells and the ability to maintain stable
long-term expression of transgenes (Matrai et al., 2010; Buch-
schacher and Wong-Staal, 2000; Sakuma et al., 2012). Due to the
inherent fragility of their native envelopes, lentiviral viral vectors
are routinely pseudotyped via transient transfection with more
stable foreign viral envelope proteins with different cell tropisms
(Cronin et al., 2005).
During the last two decades, several heterologous viral envel-
opes have been tested for lentiviral vector pseudotyping to facil-
itate efﬁcient gene transfer into various cell types (Cronin et al.,2005; Kobinger et al., 2001; Mazarakis et al., 2001; Sandrin et al.,
2002; Strang et al., 2004; Zhou and Buchholz, 2013; Schauber et
al., 2004; Trobridge et al., 2010; Kneissl et al., 2013; Zhou et al.,
2015; Witting et al., 2013). Among the ﬁrst to be used were the
ones from amphotropic retroviruses which were soon followed by
broader host tropic viral envelopes that included vesicular sto-
matitis virus (Cronin et al., 2005; Burns et al., 1993; Akkina et al.,
1996; Naldini et al., 1996). The preference for pseudotyping a
vector with a particular envelope depends on the purported use of
the vector in a particular cell type. For example, Rabies virus gly-
coprotein shows more efﬁcient gene delivery to the nervous sys-
tem, compared with VSV-G pseudotypes (Mazarakis et al., 2001).
Other envelope proteins employed for lentiviral vector pseudo-
typing include those from the measles virus, baboon retrovirus,
ﬁlovirus, baculovirus, Nipah virus, Ross river virus and Cocal virus
among others (Kobinger et al., 2001; Schauber et al., 2004; Tro-
bridge et al., 2010; Witting et al., 2013; Girard-Gagnepain et al.,
2014; Frecha et al., 2011; Kang et al., 2002). Relative to VSV-G,
some of these alternative envelope proteins achieved comparable
or better gene delivery efﬁciencies into certain tissues or cells,
such as airway epithelia and resting hematopoietic stem cells
(Kobinger et al., 2001; Girard-Gagnepain et al., 2014; Wagemaker,
2014).
As the work on gene therapy strategies progress and lentiviral
vectors continue to play a major role in gene transduction into
diverse set of target cells, there is a growing need to identify and
employ alternative viral envelopes for pseudotyping these vectors.
Fig. 1. Determination of vector titers. Vector titers were assayed on HEK293T cells.
Dilutions of the vector preparations were used to infect 5105 cells/well and the
cells were later assayed for GFP expression at 72 h post transduction to determine
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envelope for pseudotyping lentiviral vectors due to its broad host
tropism and stability, here we sought to identify and develope
related viral envelopes and evaluate their ability to generate high
titer vector stocks and transduce cells from different species. For
this reason we chose viral envelopes from the Chandipura and Piry
viruses that belong to the same vesiculovirus genus (Lyles et al.,
2013). Piry virus was originally isolated from an opossum in Brazil
and is known to cause human generalized infection (Brun et al.,
1995). Chandipura virus is an emerging pathogen in the tropical
areas of India that usually causes severe encephalitis in children
(Dhanda et al., 1970; Baquero et al., 2015). In contrast, VSV is
primarily a livestock pathogen. Based on these viruses' natural
history, different cell tropisms are expected, with Chandipura virus
to be more neurotropic. Another advantage with the use of these
new envelopes is that they are immunologically non-cross reactive
with VSV-G and thus permitting their use in vivo in a sequential
manner as an alternative to VSV-G pseudotyped vectors for
boosting gene delivery and dosage as becomes necessary (Brun et
al., 1995; Cartwright and Brown, 1972). Here our results show that
lentiviral vectors could be efﬁciently pseudotyped with the
envelopes from both these viruses, there are tropism and trans-
duction efﬁciency differences based on cell types, that the new
envelopes display stability for freeze thawing and ﬁnally, they are
relatively more resistant to exposure to human serum.the titer.Results
Lentiviral vectors can be pseudotyped with Chandipura and Piry virus
envelope glycoproteins to generate high titer vector stocks
To determine if the envelope proteins of vesiculoviruses
Chandipura and Piry can pseudotype lentiviral vectors, we pro-
duced vector particles by a standard plasmid transfection protocol.
For comparison VSV-G envelope was also used in parallel. Cell
culture supernatants (titers around 1106 TU/ml) were con-
centrated approximately 500–1000 fold by ultra-centrifugation.
The concentrated viral stocks were assayed by titration in
HEK293T cells. The titers ranged from 6.9108 to 9.1108 TU/ml
for CNV-G pseudotypes and 5.0108 to 1.4109 TU/ml for PRV-G
pseudotypes (Fig. 1). The titers observed for the VSV-G pseudo-
types were in the range of 1.1109–2.0109 TU/ml (Fig. 1). These
results showed that high titer pseudotyped lentiviral vectors can
be produced with both the novel vesiculovirus envelopes.
CNV-G and PRV-G pseudotyped lentiviral vectors can transduce dif-
ferent cell types at varying efﬁciencies
To determine the gene-delivery efﬁcacies of the novel CNV and
PRV glycoprotein pseudotyped lentiviral vectors, we employed
various lab adapted cell lines from different species that encom-
passed both adherent and non-adherent cells. VSV-G pseudotyped
vector was also used in parallel for comparison. The adherent cells
consisted of epithelial, ﬁbroblast or neuroblast origin (GHOST,
HeLa, BHK, MDCK and N2a cells) whereas the non-adherent cells
were of lymphocytic lineage (Sup-T1, CEM, Jurkat cells). The HeLa,
GHOST and T lymphocyte cell lines are of human origin whereas
the BHK, MDCK and N2a cells are of hamster, canine and murine
origin, respectively. MOI equivalents, as based on HEK293T titers,
of 0.5, 1 or 5 were used to transduce adherent cells. Varying efﬁ-
cacies of transduction with different viral envelopes could be seen
with increased transduction with increased MOI. Relative to the
VSV-G envelope, CNV-G was more efﬁcient in transducing GHOST
(88% transduction) and MDCK cells (60% transduction) with 1.2 to2 fold increase whereas similar efﬁciency were seen with HeLa and
BHK cells (85–95% transduction) at an MOI of 1 (Fig. 2A–D). By
comparison, the PRV-G was less efﬁcient in transducing all
adherent cells than VSV-G (30–80% transduction efﬁciency,
depending on cell type). For transducing neuroblastoma cells CNV-
G was found to be better than VSV-G (85% for CNV-G compared to
75% for VSV-G, at an MOI of 5), whereas PRV-G showed only
moderate transduction ability (45% transduction at an MOI of 5)
(Fig. 2E). With regard to the cells of lymphocytic origin tested at
MOI of 1, 5 and 10, both CNV-G and PRV-G were less efﬁcient than
VSV-G (60–95% for VSV-G compared to 30–70% for CNV-G and 15–
40% for PRV-G, at an MOI of 10), although CNV-G was found to be
relatively more efﬁcient than PRV-G (1.3–2.4 fold) (Fig. 2F–H).Gene transduction efﬁciencies of CNV-G and PRV-G in human PBMC
While most current gene therapy strategies involve ex vivo
gene transduction with lentiviral vectors on puriﬁed target cells,
future outlook is focused on direct systemic injection of vectors for
in vivo application. In this case, the PBMC would be the major
frontier cells to come in contact with these lentiviral vectors.
PBMC is a mixed population of cell types that include T and B
lymphocytes, monocytes/macrophages and NK cells. Here we
evaluated the transduction efﬁciency of the new pseudotyped
vectors on the mixed population of PBMC to determine which cell
type is most efﬁciently transduced. PBMC from four different
donors were tested. When the total PBMC were evaluated for gene
transduction by FACS for GFP expression, VSV-G was found to be
more efﬁcient than that of either CNV-G or PRV-G (42% for VSV-G,
compared to 5–7% for PRV-G and CNV-G at an MOI of 10- 6 to
8 fold increase) (Fig. 3A). When individual cell types were ana-
lyzed, VSV-G was again found to be more efﬁcient in all cell types
analyzed, namely, CD4 T, CD8 T, NK and B cells, with B cells being
the least efﬁcient cell type for gene transduction (Fig. 3B–E). In
general, higher MOI resulted in higher transduction levels.
Fig. 2. Transduction efﬁciencies of CNV-G, PRV-G and VSV-G pseudotyped lentiviral vectors in different cell types. (A–E) Transduction of adherent cells GHOST, HeLa, BHK,
MDCK and N2a. Cells were exposed to MOI of 0.5, 1 or 5 for 4 h and cultured for 72 h before assaying for GFP expression. Percent transduction of different cell types are
indicated. Transduction efﬁciency of CNV-G was signiﬁcantly higher than VSV-G in GHOST, MDCK and N2a cells (po0.05) (F–H) Transduction of non-adherent cells. Human
lymphoid cells (Sup-T1, CEM and Jurkat cells) were transduced at MOI of 1, 5 and 10 for 4 h and evaluated for GFP expression at 72 h. Percent transduction of different cell
types are indicated. Note that the MOIs depicted for input vector here are based on titers in HEK293T cells.
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Fig. 3. Transduction efﬁciencies of CNV-G, PRV-G and VSV-G vector pseudotypes in human peripheral blood-derived mononuclear cells (PBMC) and CD34 hematopoietic
stem cells. (A–E) PBMC and (F) CD34 cells were transduced with different vector pseudotypes at MOI of 1, 5 and 10 in the presence of polybrene for 4 h. After media change,
the cells were cultured for 72 h, stained for CD4, CD8, D19, CD56 and GFP expression assayed by FACS to determine the levels of overall transduction and that of in respective
cell types. Percent transduction for each pseudotype are indicated. Note that the MOIs depicted for input vector here are based on titers in HEK293T cells.
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Fig. 4. Resistance of CNV-G, PRV-G and VSV-G pseudotyped lentiviral vectors to
freeze/thaw cycles and human serum complement inactivation. (A) To determine
the stability of different pseudotyped vectors during freeze-thaw cycles, the vector
stocks were frozen and thawed 5 times and later titrated on HEK293T cells as
described in Methods. Results presented are from three different experiments.
(B) To determine the vector sensitivity to human serum complement, vector pre-
parations were exposed to control and heat inactivated human sera for 1 h at 37 °C.
Later, the exposed vector suspensions were titered on HEK293T cells. Titer values
obtained from DMEM media exposure alone were set as baseline and compared
with those of exposure to heat inactivated and non-inactivated sera treatment.
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For sustained transgene expression in the cells of hematopoi-
etic lineage, VSV-G pseudotyped lentiviral vectors are routinely
used to transducer CD34 hematopoietic stem cells. Here we eval-
uated CNV-G and PRV-G to determine their efﬁciency on these
cells at MOI of 1, 5 and 10. Cells from different donors were used in
separate set of experiments to verify the results. Increasing
transduction efﬁciencies were seen as expected with increased
MOI with all three pseudotypes (Fig. 3F). Whereas VSV-G pseu-
dotype showed an impressive transduction efﬁciency reaching up
to 80%, the CNV-G and PRV-G pseudotypes showed much lower
efﬁciencies of 10% and 15% respectively, at an MOI of 10. These
data demonstrate that CNV-G and PRV-G have a narrower cell
tropism compared to the broad cell tropic VSV-G.
Pseudotyped vector stability during freeze/thaw cycles
One of the practical considerations for lentiviral-based gene
therapy is the stability of pseudotyped HIV-1 vectors during sto-
rage and freeze/thaw cycles (Strang et al., 2004; Akkina et al.,
1996). This aspect was examined by vector titration on HEK293T
cells, after cycling between –80 °C and 37 °C successively for ﬁve
times. The relative titer at each freeze/thaw cycle was compared to
the starting point titer for each vector pseudotype and is pre-
sented in Fig. 4A. All three pseudotypes behaved similarly, with
moderate resistance to freeze/thaw cycles showing about a 10%
decrease in titer after each cycle. There was no signiﬁcant differ-
ence in the stability among the three pseudotypes (p40.05). After
ﬁve freeze/thaw cycles, all pseudotypes still maintained 50% of
their original titers, indicating their relative resistance to the
damage from freeze/thaw cycling.
Resistance to inactivation by human sera
VSV-G pseudotyped vectors are prone to inactivation by human
serum complement, thus limiting their effectiveness in vivo. Here
we evaluated the serum complement sensitivity of CNV-G and
PRV-G and compared it to that of VSV-G. Five sera from different
donors were used for testing (Fig. 4B). While VSV-G pseudotype
was inactivated signiﬁcantly with a 70–80% reduction in the
overall titer, the PRV-G pseudotype showed only 10–45% drop and
CNV-G pseudotype decreased in titer by 45–65%. Overall, the
resistance of CNV-G and PRV-G to serum inactivation relative to
that of VSV-G is signiﬁcant (po0.05), thus indicating the relative
stability of these for in vivo use.Discussion
Gene transduction with lentiviral vectors is among the most
efﬁcient methods for gene delivery due to the capacity of these
vectors to transduce a variety of both dividing and non-diving
cells. Heterologous viral envelope glycoprotein G from the Vesi-
culovirus, vesicular stomatitis virus, due to its broad host cell
tropism has greatly facilitated transduction of many cell types.
However, the relative susceptibility of VSV-G to serum comple-
ment inactivation and other drawbacks such as cell toxicity has
somewhat hampered its utility for broader applications that
include direct in vivo gene delivery (Schauber et al., 2004; Tro-
bridge et al., 2010; Yao et al., 2003). Here in an effort to identify
alternative heterologous viral envelopes for vector pseudotyping,
we evaluated two related viral envelopes from Chandipura and
Piry viruses that belong to the same Vesiculovirus genus like VSV.
While both these viruses are phylogenetically related to VSV, theyare serologically distinct and with different cell tropisms (Brun et
al., 1995; Cartwright and Brown, 1972).
Here we showed that lentiviral vectors can be pseudotyped
with either of these heterologous viral envelopes. High titer vector
stocks yielding more than 5108 TU/ml can be prepared by con-
centration via ultra-centrifugation, suggesting that these envel-
opes are relatively stable compared to retroviral envelopes (Stitz et
al., 2000). When the transduction efﬁciencies were compared with
that of VSV-G pseudotyped lentiviral vectors, CNV-G pseudotyped
vectors were found to be relatively more efﬁcient in transducing
GHOST and MDCK cells whereas PRV-G was less efﬁcient than both
CNV-G and VSV-G. Conﬁrming its neurotropism, CNV-G showed
higher transduction into neuroblastoma cells than either VSV-G or
PRV-G. In human T cell lines, transduction levels achieved with
CNV-G were higher than that of PRV-G, while transduction of
these cell lines with VSV-G was found to be far superior. In a
mixed PBMC population, the transduction efﬁciencies of both the
CNV-G and PRV-G were found to be far lower than that of VSV-G in
transducing CD4T, CD8T, NK and B cells. For the treatment of blood
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lentiviral vector mediated transduction with VSV-G pseudotyped
vectors (Wagemaker, 2014; Salmon et al., 2000). Here we found
that both CNV-G and PRV-G, while capable of transducing CD34
cells, their levels of transduction were much lower than that of
VSV-G. Transducing the cells twice at an MOI of 10 or increasing
the MOI to 20 resulted in only a marginal increase in gene transfer
(data not shown). We also determined that the lower transduction
level seen in CD34 cells was not due to possible toxicity of these
envelopes (data not shown). It is interesting to note that, with
regard to gene transduction of hematopoietic CD34 progenitor
cells with yet another related vesiculovirus, higher transduction
levels were reported with a lentiviral vector pseudotyped with
Cocal virus glycoprotein compared to that of VSV-G (Trobridge et
al., 2010). The higher transduction observed with Cocal viral
envelope on CD34 cells than with either CNV-G or PRV-G is most
likely due to the reason that Cocal virus is also a broad host tropic
virus like VSV that can infect a much wider species of animals
including livestock (Trobridge et al., 2010).
With regard to stability, both CNV-G and PRV-G pseudotypes
showed comparable results to VSV-G during successive freeze/
thaw cycles wherein a 10% drop in titer was observed with each
cycle. A common drawback with the VSV-G pseudotyped vectors
is their sensitivity to inactivation by human complement present
in the human sera. By comparison, PRV-G pseudotype was highly
resistant to human sera complement components, registering
only a slight decline in its titer after incubation with sera from
ﬁve different donors. CNV-G pseudotype showed some level of
inactivation by human sera, but still had much higher titer than
VSV-G pseudotype. A recent study determined that VSV-G neu-
tralization or inactivation by human sera is mediated by con-
certed actions of natural IgM and complement and that a related
vesiculovirus, Maraba virus, G protein is relatively resistant to
this phenomenon (Tesfay et al., 2014). The marked resistance
shown here by PRV-G and CNV-G to human serum exposure
might be similar to that of Maraba virus G protein and thus
confers an advantage over VSV-G pseudotyped vectors for their
future use in in vivo applications.
For sustained gene expression and boosting gene dosage
in vivo, it may be necessary to employ repeated administration of
vectored genes. Use of a single pseudotyped vector for multiple
injections will invariably lead to immune response to the envelope
thus eventually precluding its utility. In such a scenario, using
CNV-G and PRV-G pseudotyped vectors sequentially will help
overcome the immune response mounted against VSV-G pseudo-
typed lentiviral vectors for subsequent vector administration.
In conclusion, Chandipura and Piry virus envelope glycopro-
teins mediated efﬁcient transduction of several target cell types
including ﬁbroblastic and epithelial from different species. CNV-G
pseudotyped vectors transduced these cells at a similar or better
efﬁciency than VSV-G pseudotypes. While relatively less efﬁcient,
PRV-G pseudotyped vectors also showed gene delivery efﬁciencies
at levels adequate for experimentation and thus provide a good
alternative when necessary. However, the new envelopes were
sub-optimal in mediating gene transduction into non-adherent
cell types such as lymphoid cells and hematopoietic stem cells.
Nevertheless, the CNV-G and PRV-G pseudotyped vectors are
expected to ﬁll a gap when alternative envelope proteins are
needed to transduce a particular cell type and when neutralizing
immune responses preclude the use of the standard VSV-G pseu-
dotyped vectors for in vivo gene delivery.Materials and methods
Cells and envelope expression plasmids
HEK293T cell line was used to generate pseudotyped lentiviral
vectors with different vesiculovirus envelopes. Different adherent
cell types, namely GHOST, HeLa, BHK, MDCK and N2a cells were
used for evaluating vector transductions. These cells were cultured
and maintained in DMEM containing 10% FBS. Non-adherent cell
lines consisted of human T lymphoid cells Sup-T1, CEM and Jurkat.
These cells were maintained in RPMI media supplemented with
10% FBS. Human peripheral blood-derived mononuclear cells
(PBMC) from unidentiﬁed donors were cultured in RPMI media
supplemented with 10% FBS and IL-2. For hematopoietic stem cell
transductions, human fetal liver derived CD34 cells were used
which were cultivated in IL-3, IL-6 and SCF cytokine media. Piry
and Chandipura viruses were obtained from Dr. R. E. Shope, Uni-
versity of Texas, Galveston. Viral G protein genes were ampliﬁed
by RT-PCR and cloned into pTARGET expression plasmid contain-
ing CMV promoter. The heterologous envelope gene containing
plasmids VSV-G, CNV-G and PRV-G were used to produce pseu-
dotyped lentiviral vectors. The third generation lentiviral vector
backbone contains an EGFP reporter (Anderson et al., 2007; Akkina
et al., 1996; Li et al., 2005).
Vector production, concentration and titration
A standard lentiviral vector production protocol was used as
described previously (Anderson et al., 2007; Akkina et al., 1996; Li
et al., 2005). Brieﬂy, plasmids encoding the transfer vector with
the EGFP reporter, rev, packaging proteins and the heterologous
envelope were co-transfected into HEK293T cells. Vector super-
natants were collected at 24, 48 and 72 h after transfection and
concentrated by ultra-centrifugation. Vector titers were deter-
mined by FACS analysis of transduced cells as described previously
(Anderson et al., 2007; Akkina et al., 1996; Li et al., 2005). For
infecting different cell types at a certain MOI, the HEK293T cell
titers were used to depict the input MOI.
Determination of gene transduction efﬁciency of pseudotyped vectors
in different cell types
For adherent cell vector transductions, HeLa, BHK, GHOST,
MDCK and mouse neuroblastoma cell line N2a were used. Brieﬂy,
1105 cells were transduced with MOI of 0.5 and 1 in the pre-
sence of polybrene (8 mg/ml), except for N2a where an MOI of
1 and 5 were evaluated. As mentioned above, the MOIs depicted
for transducing each cell type were based on TU titers obtained
from vector titration on HEK293T cells. Four hours after incubation
with the vector, the cells were cultured for 72 h followed by FACS
analysis for GFP expression. For non-adherent cell transductions,
the human T cell lines CEM, Sup-T1 and Jurkat cells were used.
MOI of 1, 5 and 10 were evaluated. For transduction of PBMC, the
cells were cultured in the presence of IL-2 and PHA for 72 h to
derive lymphoblasts. Half a million expanded PBMC were exposed
to the vectors at MOI of 1, 5 and 10 for 4 h. Post-transduction, cells
were cultured for 72 h followed by FACS analysis for GFP expres-
sion. To determine the transduction efﬁciencies on different cell
types in PBMC, various cell surface markers were used and ana-
lyzed by FACS. Brieﬂy, cells were stained with CD3 Alexa Fluor 700,
CD4 PE-Cy5, CD8 Paciﬁc Blue, D19 PE and CD56 PE-Cy7 (all anti-
bodies were obtained from BD Pharmingen). Stained samples were
analyzed on Coulter CANTO II FACS instrument to determine GFP
expression in various cell lineages. To determine gene transduc-
tion efﬁciency in human hematopoietic cells, human fetal liver
derived CD34 cells were used. The cells were cultured in cytokine
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tion, 1105 cells were exposed to the vector at MOI of 1, 5 and 10
in the presence of 8 mg/ml polybrene for 4 h followed by media
change. Transduced cells were analyzed by FACS for GFP expres-
sion 72 h later.
Determination of pseudotyped vector sensitivity to human serum
complement
To determine the vector sensitivity to human serum comple-
ment components, vector preparations were exposed to control
and heat inactivated human sera (Schauber et al., 2004; Trobridge
et al., 2010). DMEM media was used as non-serum control for
vector exposure. Five different human sera were used. Brieﬂy,
1107 TU of the vector was mixed with the respective sera and
incubated for 1 h at 37 °C. Later the exposed vector suspension
was titered on HEK293T cells and assayed by FACS for GFP. The
titer values seen with DMEM media exposure were set as baseline
and compared with those of exposure to heat-inactivated and
non-inactivated sera treatment.
Statistical analysis
To assess the signiﬁcance of differences seen among the three
pseudotypes, statistical analysis was used to evaluate data from
multiple experiments using GraphPad Prism version 6 (GraphPad
Software, USA). Student’s unpaired t-test was used to compare the
transduction efﬁciencies. Two-way ANOVA grouped test was used
to evaluate the resistance to freeze/thaw cycles. Mann–Whitney u
test was used to analyze the resistance to human serum comple-
ment. P values less than 0.05 were considered to be signiﬁcant.Acknowledgments
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